Borer Denton & Associates’s AstraZeneca AZN Stock Holding History

Borer Denton & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$378K	Buy	2,017 +390	+24%	+$73.4K	0.12%	59
2026 Q1	$315K	Buy	1,627 +77	+5%	+$14.8K	0.11%	61
2025 Q4	$285K	Buy	+1,550	New	+$272K	0.1%	60

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Borer Denton & Associates's AZN Position: Q2 2026 in Review

Borer Denton & Associates increased its AstraZeneca (AZN) stake by 24% in Q2 2026, buying an estimated $73.4K and bringing the position to 2,017 shares worth $378K. The position accounts for 0.12% of the portfolio, ranked #59.

Borer Denton & Associates first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Borer Denton & Associates held 2,017 shares of AstraZeneca worth $378K as of Q2 2026.
Borer Denton & Associates bought 390 AstraZeneca shares in Q2 2026, an estimated $73.4K.
AstraZeneca made up 0.12% of Borer Denton & Associates's portfolio in Q2 2026, its #59 holding.
Borer Denton & Associates first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Borer Denton & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.